|
Emsam (selegiline transdermal system) is the trade name of an antidepressant of the monoamine oxidase inhibitor (MAOI) class. Emsam is a transdermal patch containing the MAOI selegiline. Selegiline, in small doses, is most commonly used in the treatment of Parkinson's disease. Emsam is also used, in higher doses, for the treatment of major depressive disorder.〔 〕 On February 28, 2006, the U.S. Food and Drug Administration (FDA) approved Emsam for the treatment of major depression.〔 〕〔 〕〔 〕 ==Inception and development== Emsam's development was spearheaded by J. Alexander Bodkin, M.D.,〔 (【引用サイトリンク】title=Alexander J. Bodkin, M.D. )〕 Director of the Clinical Psychopharmacology Research Program at McLean Hospital in Belmont, Massachusetts, in conjunction with Harvard Medical School.〔(FDA Approves EMSAM(R) (selegiline Transdermal System), The First Transdermal Patch For The Treatment Of Major Depressive Disorder )〕 〔 〕 〔 〕 Currently, it is the only MAOI on the market used in the treatment of depression that is absorbed through the skin into the bloodstream and thereby to the central nervous system. The patch "is a matrix containing three layers consisting of a backing, an... adhesive drug layer, and a release liner that is placed against the skin."〔 The primary advantage of delivering selegiline in this manner is to bypass the gastrointestinal tract and liver, specifically the small intestine, thereby limiting the chance of hypertensive crisis (very high spike in blood pressure possibly leading to stroke).〔 〔 (【引用サイトリンク】title=Hypertensive Crisis )〕 〔 〕 "Despite long-standing concerns over hypertensive reactions,... (MAOIs) have grown in popularity... (and) the risk of hypertensive episodes is less than 1%." 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Emsam」の詳細全文を読む スポンサード リンク
|